

# Ravi A Madan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/51250/publications.pdf>

Version: 2024-02-01

164  
papers

6,613  
citations

81839

39  
h-index

85498

71  
g-index

167  
all docs

167  
docs citations

167  
times ranked

7897  
citing authors

#	ARTICLE	IF	CITATIONS
1	Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. <i>Lancet Oncology</i> , The, 2012, 13, 501-508.	5.1	333
2	Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGF $\beta$ 2, in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2018, 24, 1287-1295.	3.2	304
3	Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 663-674.	2.0	279
4	Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. <i>Lancet Oncology</i> , The, 2017, 18, 587-598.	5.1	261
5	Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic Efficacy. <i>Clinical Cancer Research</i> , 2011, 17, 907-917.	3.2	224
6	Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations. , 2018, 6, 141.		214
7	Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 1001-1011.	1.9	187
8	Immunotherapy of Prostate Cancer: Facts and Hopes. <i>Clinical Cancer Research</i> , 2017, 23, 6764-6770.	3.2	173
9	Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors. , 2019, 7, 240.		162
10	Analysis of Overall Survival in Patients with Nonmetastatic Castration-Resistant Prostate Cancer Treated with Vaccine, Nilutamide, and Combination Therapy. <i>Clinical Cancer Research</i> , 2008, 14, 4526-4531.	3.2	141
11	Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	139
12	Phase II Trial of Bevacizumab, Thalidomide, Docetaxel, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 2070-2076.	0.8	136
13	Therapeutic Cancer Vaccines in Prostate Cancer: The Paradox of Improved Survival Without Changes in Time to Progression. <i>Oncologist</i> , 2010, 15, 969-975.	1.9	131
14	Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy. <i>Oncologist</i> , 2019, 24, 1259-1269.	1.9	127
15	Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury. <i>Cancer Immunology Research</i> , 2015, 3, 1248-1256.	1.6	118
16	First-in-Human Phase I Trial of a Tumor-Targeted Cytokine (NHS-IL12) in Subjects with Metastatic Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 99-109.	3.2	116
17	Immune Impact Induced by PROSTVAC (PSA-TRICOM), a Therapeutic Vaccine for Prostate Cancer. <i>Cancer Immunology Research</i> , 2014, 2, 133-141.	1.6	115
18	A Pilot Study of MUC-1/CEA/TRICOM Poxviral-Based Vaccine in Patients with Metastatic Breast and Ovarian Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 7164-7173.	3.2	111

#	ARTICLE	IF	CITATIONS
19	Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role. <i>Blood</i> , 2012, 120, 3030-3038.	0.6	107
20	The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells. <i>Oncotarget</i> , 2016, 7, 37762-37772.	0.8	96
21	Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma. , 2019, 7, 269.		94
22	Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 225-234.	2.0	86
23	A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 407-418.	2.0	82
24	Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer. <i>JAMA Oncology</i> , 2015, 1, 1087.	3.4	80
25	Bintrafusp alfa, a bifunctional fusion protein targeting TGF- $\beta$ 2 and PD-L1, in patients with human papillomavirus-associated malignancies. , 2020, 8, e001395.		79
26	Prospective Study Evaluating Na <sup>18</sup> F PET/CT in Predicting Clinical Outcomes and Survival in Advanced Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 886-892.	2.8	78
27	Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody. , 2017, 5, 20.		78
28	Clinical Evaluation of TRICOM Vector Therapeutic Cancer Vaccines. <i>Seminars in Oncology</i> , 2012, 39, 296-304.	0.8	75
29	The Kinetics and Reproducibility of <sup>18</sup> F-Sodium Fluoride for Oncology Using Current PET Camera Technology. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1175-1184.	2.8	71
30	PANVAC $\alpha$ -VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma. <i>Expert Opinion on Biological Therapy</i> , 2007, 7, 543-554.	1.4	70
31	Therapeutic Cancer Vaccines. <i>Advances in Cancer Research</i> , 2014, 121, 67-124.	1.9	68
32	Enhancing efficacy of therapeutic vaccinations by combination with other modalities. <i>Vaccine</i> , 2007, 25, B89-B96.	1.7	63
33	Overcoming Chemotherapy Resistance in Prostate Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 3892-3902.	3.2	61
34	Soluble CD27-Pool in Humans May Contribute to T Cell Activation and Tumor Immunity. <i>Journal of Immunology</i> , 2013, 190, 6250-6258.	0.4	59
35	Disparities in Cancer Care and the Asian American Population. <i>Oncologist</i> , 2021, 26, 453-460.	1.9	59
36	A phase I study of TRC105 anti $\alpha$ endoglin (CD105) antibody in metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2015, 116, 546-555.	1.3	55

#	ARTICLE	IF	CITATIONS
37	Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 197-206.	2.0	51
38	Endocrine-Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management. <i>Oncologist</i> , 2020, 25, 290-300.	1.9	51
39	Phase I Study of a Poxviral TRICOM-Based Vaccine Directed Against the Transcription Factor Brachyury. <i>Clinical Cancer Research</i> , 2017, 23, 6833-6845.	3.2	51
40	Nivolumab: Promising Survival Signal Coupled With Limited Toxicity Raises Expectations. <i>Journal of Clinical Oncology</i> , 2014, 32, 986-988.	0.8	50
41	Analyses of 123 Peripheral Human Immune Cell Subsets: Defining Differences with Age and between Healthy Donors and Cancer Patients Not Detected in Analysis of Standard Immune Cell Types. <i>Journal of Circulating Biomarkers</i> , 2016, 5, 5.	0.8	50
42	Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy. <i>European Urology</i> , 2021, 80, 746-757.	0.9	50
43	PART V. Modulation of Antitumor Vaccine Strategies Preclinical and Clinical Studies of Recombinant Poxvirus Vaccines for Carcinoma Therapy. <i>Critical Reviews in Immunology</i> , 2007, 27, 451-462.	1.0	49
44	A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules. <i>Clinical Cancer Research</i> , 2019, 25, 4933-4944.	3.2	45
45	Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T. <i>Journal of the National Cancer Institute</i> , 2020, 112, 562-573.	3.0	45
46	Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer. , 2020, 8, e000655.		41
47	Phase I clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2013, 111, 1269-1280.	1.3	40
48	A Phase II Clinical Trial of TRC105 (Anti-Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 77-85.	0.9	40
49	A Prospective Comparison of <sup>18</sup> F-Sodium Fluoride PET/CT and PSMA-Targeted <sup>18</sup> F-DCFBC PET/CT in Metastatic Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1665-1671.	2.8	40
50	A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)-Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer. <i>Oncologist</i> , 2020, 25, 479-e899.	1.9	39
51	Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1521-1531.	2.0	38
52	Samarium-153-EDTMP (Quadramet®) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial. <i>Oncotarget</i> , 2016, 7, 69014-69023.	0.8	38
53	Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy. <i>Cancer Immunology Research</i> , 2016, 4, 755-765.	1.6	36
54	Combining immunotherapies for the treatment of prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 694-700.	0.8	36

#	ARTICLE	IF	CITATIONS
55	Therapeutic vaccines in metastatic castration-resistant prostate cancer: principles in clinical trial design. <i>Expert Opinion on Biological Therapy</i> , 2010, 10, 19-28.	1.4	32
56	The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic. <i>Oncotarget</i> , 2015, 6, 31344-31359.	0.8	32
57	Up-regulation of proliferative and migratory genes in regulatory T cells from patients with metastatic castration-resistant prostate cancer. <i>International Journal of Cancer</i> , 2013, 133, 373-382.	2.3	31
58	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma. , 2016, 4, 92.		31
59	Randomized, Double-Blind, Placebo-Controlled Phase II Study of Yeast-Brachyury Vaccine (GI-6301) in Combination with Standard-of-Care Radiotherapy in Locally Advanced, Unresectable Chordoma. <i>Oncologist</i> , 2021, 26, e847-e858.	1.9	31
60	The Role of Sipuleucel-T in Therapy for Castration-Resistant Prostate Cancer: A Critical Analysis of the Literature. <i>European Urology</i> , 2012, 61, 639-647.	0.9	28
61	A case report of multiple primary prostate tumors with differential drug sensitivity. <i>Nature Communications</i> , 2020, 11, 837.	5.8	28
62	Cabozantinib-Induced Thyroid Dysfunction: A Review of Two Ongoing Trials for Metastatic Bladder Cancer and Sarcoma. <i>Thyroid</i> , 2014, 24, 1223-1231.	2.4	27
63	Randomized phase II trial of docetaxel with or without PSA-TRICOM vaccine in patients with castrate-resistant metastatic prostate cancer: A trial of the ECOG-ACRIN cancer research group (E1809). <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 2469-2474.	1.4	26
64	Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC). , 2021, 9, e002374.		25
65	PSA-based vaccines for the treatment of prostate cancer. <i>Expert Review of Vaccines</i> , 2006, 5, 199-209.	2.0	24
66	A pilot safety trial investigating a vector-based vaccine targeting carcinoembryonic antigen in combination with radiotherapy in patients with gastrointestinal malignancies metastatic to the liver. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 1409-1418.	1.4	24
67	Therapeutic Cancer Vaccines. <i>American Journal of Therapeutics</i> , 2012, 19, e172-e181.	0.5	24
68	TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancer. <i>Oncolmmunology</i> , 2016, 5, e1197459.	2.1	24
69	Evaluating Biochemically Recurrent Prostate Cancer: Histologic Validation of <sup>18</sup> F-DCFPyL PET/CT with Comparison to Multiparametric MRI. <i>Radiology</i> , 2020, 296, 564-572.	3.6	24
70	Sipuleucel-T: harbinger of a new age of therapeutics for prostate cancer. <i>Expert Review of Vaccines</i> , 2011, 10, 141-150.	2.0	23
71	Phase II Study of Satraplatin and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer: A Pharmacogenetic Assessment of Outcome and Toxicity. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 229-237.	0.9	23
72	Phase trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2016, 118, 590-597.	1.3	23

#	ARTICLE	IF	CITATIONS
73	Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic Response. <i>Clinical Cancer Research</i> , 2021, 27, 429-437.	3.2	22
74	Combining vaccines with conventional therapies for cancer. <i>Update on Cancer Therapeutics</i> , 2007, 2, 33-39.	0.9	21
75	Immunotherapy in prostate cancer: Emerging strategies against a formidable foe. <i>Vaccine</i> , 2011, 29, 6485-6497.	1.7	20
76	From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer. <i>Expert Review of Vaccines</i> , 2011, 10, 743-753.	2.0	20
77	Demystifying Immunotherapy in Prostate Cancer. <i>Cancer Journal (Sudbury, Mass )</i> , 2013, 19, 50-58.	1.0	20
78	Considerations for the combination of anticancer vaccines and immune checkpoint inhibitors. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 895-901.	1.4	20
79	Combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity. <i>Oncolmmunology</i> , 2012, 1, 1167-1168.	2.1	19
80	Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer. , 2021, 9, e003238.		19
81	Recent advances revolutionize treatment of metastatic prostate cancer. <i>Future Oncology</i> , 2013, 9, 1133-1144.	1.1	18
82	Ferumoxytol-Enhanced MR Lymphography for Detection of Metastatic Lymph Nodes in Genitourinary Malignancies: A Prospective Study. <i>American Journal of Roentgenology</i> , 2020, 214, 105-113.	1.0	17
83	Phase I Trial of a Modified Vaccinia Ankara Priming Vaccine Followed by a Fowlpox Virus Boosting Vaccine Modified to Express Brachyury and Costimulatory Molecules in Advanced Solid Tumors. <i>Oncologist</i> , 2020, 25, 560.	1.9	17
84	A Randomized, Double-blind, Phase II Trial of PSA-TRICOM (PROSTVAC) in Patients with Localized Prostate Cancer: The Immunotherapy to Prevent Progression on Active Surveillance Study. <i>European Urology Focus</i> , 2018, 4, 636-638.	1.6	16
85	Exploiting Synergy: Immune-Based Combinations in the Treatment of Prostate Cancer. <i>Frontiers in Oncology</i> , 2014, 4, 351.	1.3	15
86	Phase I/II Trial of Vandetanib and Bortezomib in Adults with Locally Advanced or Metastatic Medullary Thyroid Cancer. <i>Oncologist</i> , 2019, 24, 16-e14.	1.9	15
87	Poxviral-based vaccine elicits immunologic responses in prostate cancer patients. <i>Oncolmmunology</i> , 2014, 3, e28611.	2.1	14
88	A Case Report of Sequential Use of a Yeast-CEA Therapeutic Cancer Vaccine and Anti-PD-L1 Inhibitor in Metastatic Medullary Thyroid Cancer. <i>Frontiers in Endocrinology</i> , 2020, 11, 490.	1.5	14
89	The World of Clinical Trial Development Post COVID-19: Lessons Learned from a Global Pandemic. <i>Clinical Cancer Research</i> , 2020, 26, 4198-4200.	3.2	14
90	Beyond PSA: Managing Modern Therapeutic Options in Metastatic Castration-Resistant Prostate Cancer. <i>Southern Medical Journal</i> , 2015, 108, 224-228.	0.3	14

#	ARTICLE	IF	CITATIONS
91	Therapeutic Vaccines and Immunotherapy in Castration-Resistant Prostate Cancer: Current Progress and Clinical Applications. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, 33, e166-e170.	1.8	13
92	A comparison of prostate cancer bone metastases on 18F-Sodium Fluoride and Prostate Specific Membrane Antigen (18F-PSMA) PET/CT: Discordant uptake in the same lesion. Oncotarget, 2018, 9, 37676-37688.	0.8	13
93	Perspectives on the clinical development of immunotherapy in prostate cancer. Asian Journal of Andrology, 2018, 20, 253.	0.8	13
94	Lutetium-177-PSMA-617: A Vision of the Future. Cancer Biology and Therapy, 2022, 23, 186-190.	1.5	13
95	Therapeutic cancer vaccine fulfills the promise of immunotherapy in prostate cancer. Immunotherapy, 2011, 3, 27-31.	1.0	12
96	Measurement of NLG207 (formerly CRLX101) nanoparticle-bound and released camptothecin in human plasma. Journal of Pharmaceutical and Biomedical Analysis, 2020, 181, 113073.	1.4	12
97	Deep Learning Based Staging of Bone Lesions From Computed Tomography Scans. IEEE Access, 2021, 9, 87531-87542.	2.6	12
98	A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1). Prostate Cancer and Prostatic Diseases, 2022, 25, 735-740.	2.0	12
99	Strategies for Optimizing the Clinical Impact of Immunotherapeutic Agents Such as Sipuleucel-T in Prostate Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 1505-1512.	2.3	11
100	Developing immunotherapy strategies in the treatment of prostate cancer. Asian Journal of Urology, 2016, 3, 278-285.	0.5	11
101	Novel immunotherapy combinations for genitourinary cancers. Expert Opinion on Biological Therapy, 2020, 20, 253-262.	1.4	11
102	The Current and Emerging Role of Immunotherapy in Prostate Cancer. Clinical Genitourinary Cancer, 2010, 8, 10-16.	0.9	10
103	The evolving role of immunotherapy in prostate cancer. Current Opinion in Oncology, 2016, 28, 232-240.	1.1	10
104	Population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of NLG207 in adults with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2020, 86, 475-486.	1.1	10
105	The immunotherapy revolution in genitourinary malignancies. Immunotherapy, 2020, 12, 819-831.	1.0	10
106	Vaccines as Monotherapy and in Combination Therapy for Prostate Cancer. Clinical and Translational Science, 2010, 3, 116-122.	1.5	9
107	Effect of Talactoferrin Alfa on the Immune System in Adults With Non-small Cell Lung Cancer. Oncologist, 2013, 18, 821-822.	1.9	9
108	Detection and Characterization of Circulating Tumour Cells from Frozen Peripheral Blood Mononuclear Cells. Journal of Circulating Biomarkers, 2015, 4, 4.	0.8	9

#	ARTICLE	IF	CITATIONS
109	Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer. , 2021, 9, e001556.		9
110	Charting a Path Towards Asian American Cancer Health Equity: A Way Forward. Journal of the National Cancer Institute, 2022, 114, 792-799.	3.0	9
111	Treatment of Castration-Resistant Prostate Cancer: Updates on Therapeutics Targeting the Androgen Receptor Signaling Pathway. American Journal of Therapeutics, 2010, 17, 176-181.	0.5	8
112	Prostate cancer immunotherapy: the path forward. Current Opinion in Supportive and Palliative Care, 2017, 11, 225-230.	0.5	8
113	Protein kinase inhibitors for the treatment of prostate cancer. Expert Opinion on Pharmacotherapy, 2021, 22, 1889-1899.	0.9	8
114	Ipilimumab in prostate cancer. Expert Opinion on Biological Therapy, 2013, 13, 303-313.	1.4	7
115	Is It Time to Reevaluate Definitive Therapy in Prostate Cancer?. Journal of the National Cancer Institute, 2013, 105, 683-685.	3.0	7
116	The Potential Role for Immunotherapy in Biochemically Recurrent Prostate Cancer. Urologic Clinics of North America, 2020, 47, 457-467.	0.8	7
117	Cabozantinib plus docetaxel and prednisone in metastatic castration-resistant prostate cancer. BJU International, 2021, 127, 435-444.	1.3	7
118	Angiogenesis Inhibition in the Treatment of Prostate Cancer. Anti-Cancer Agents in Medicinal Chemistry, 2009, 9, 1070-1078.	0.9	6
119	Immunotherapy in genitourinary malignancies. Current Opinion in Urology, 2016, 26, 501-507.	0.9	6
120	Metabolic syndrome in prostate cancer: impact on risk and outcomes. Future Oncology, 2016, 12, 1947-1955.	1.1	6
121	Identification by digital immunohistochemistry of intratumoral changes of immune infiltrates after vaccine in the absence of modifications of PBMC immune cell subsets. International Journal of Cancer, 2014, 135, 862-870.	2.3	5
122	Therapeutic vaccines for prostate cancer: recent advances and future directions. Expert Review of Vaccines, 2016, 15, 907-914.	2.0	5
123	Prospects for the future of prostate cancer vaccines. Expert Review of Vaccines, 2016, 15, 271-274.	2.0	5
124	Targeting the Tumor Microenvironment with Immunotherapy for Genitourinary Malignancies. Current Treatment Options in Oncology, 2018, 19, 16.	1.3	5
125	A Case of Anti-“PD-L1-associated Remitting Seronegative Symmetric Synovitis With Pitting Edema. Clinical Genitourinary Cancer, 2019, 17, e549-e552.	0.9	5
126	Phase II trial of bevacizumab and lenalidomide with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2012, 30, 207-207.	0.8	5



#	ARTICLE	IF	CITATIONS
127	Cancer vaccines: current directions and perspectives in prostate cancer. <i>Current Opinion in Molecular Therapeutics</i> , 2009, 11, 31-6.	2.8	5
128	Abiraterone. <i>Cougar Biotechnology. IDrugs: the Investigational Drugs Journal</i> , 2006, 9, 49-55.	0.7	5
129	With New Technology Comes Great Responsibility: Prostate-Specific Membrane Antigen Imaging in Recurrent Prostate Cancer. <i>Journal of Clinical Oncology</i> , 0, , .	0.8	5
130	(R)Evolutionary Therapy: The Potential of Immunotherapy to Fulfill the Promise of Personalized Cancer Treatment. <i>Journal of the National Cancer Institute</i> , 2014, 107, dju347-dju347.	3.0	4
131	Recent advances in the use of therapeutic cancer vaccines in genitourinary malignancies. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 1769-1781.	1.4	4
132	Evaluating immune responses after sipuleucel-T therapy. <i>Cancer Biology and Therapy</i> , 2015, 16, 1119-1121.	1.5	4
133	A population pharmacokinetic analysis of the oral CYP17 lyase and androgen receptor inhibitor seviteronel in patients with advanced/metastatic castration-resistant prostate cancer or breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 759-770.	1.1	4
134	Significant Prostate-Specific Antigen (PSA) Response to Low-Dose Ketoconazole in a Patient With Non-Metastatic Androgen-Independent Prostate Cancer (AIPC) and a Review of the Literature. <i>American Journal of Therapeutics</i> , 2007, 14, 310-313.	0.5	3
135	Therapeutic Cancer Vaccines in Prostate Cancer: The Quest for Intermediate Markers of Response. <i>Cancers</i> , 2012, 4, 1229-1246.	1.7	3
136	Initial PSA Oscillations Precede Prolonged Stable Disease in a Patient Treated With a Therapeutic Cancer Vaccine. <i>Clinical Genitourinary Cancer</i> , 2012, 10, 43-46.	0.9	3
137	Moving the goal posts in prostate cancer trials. <i>Lancet Oncology, The</i> , 2015, 16, 247-249.	5.1	3
138	Integrating Immunotherapies in Prostate Cancer. <i>Current Oncology Reports</i> , 2015, 17, 45.	1.8	3
139	A Phase II Multi-Center Study of Bevacizumab in Combination with Ixabepilone in Subjects with Advanced Renal Cell Carcinoma. <i>Oncologist</i> , 2017, 22, 888.	1.9	3
140	Spotlight on atezolizumab and its potential as an oncology agent. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 719-722.	1.1	3
141	Behind the IL-8 ball in prostate cancer. <i>Nature Cancer</i> , 2021, 2, 775-776.	5.7	3
142	The path forward in prostate cancer therapeutics. <i>Asian Journal of Andrology</i> , 2018, 20, 213.	0.8	3
143	A Single-arm Phase II Study Combining NLG207, a Nanoparticle Camptothecin, with Enzalutamide in Advanced Metastatic Castration-resistant Prostate Cancer Post-Enzalutamide. <i>Oncologist</i> , 2022, 27, 718-e694.	1.9	3
144	The impact of leukapheresis on immune-cell number and function in patients with advanced cancer. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1429-1435.	2.0	2

#	ARTICLE	IF	CITATIONS
145	The Winds of Change: Emerging Therapeutics in Prostate Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 382-390.	1.8	2
146	Exploiting defects in homologous recombination repair for metastatic, castration-resistant prostate cancer. Cancer Biology and Therapy, 2020, 21, 884-887.	1.5	2
147	Study to Compare Capsule and Liquid Formulations of Enzalutamide After <scp>Single-Dose</scp> Administration Under Fasting Conditions in Prostate Cancer. Oncologist, 2021, 26, 729-e1493.	1.9	2
148	Modern immunotherapy for the treatment of prostate cancer. Drug Discovery Today: Therapeutic Strategies, 2010, 7, 37-42.	0.5	1
149	Intermediate efficacy end points to assess modern therapies. Nature Reviews Urology, 2013, 10, 686-687.	1.9	1
150	Abiraterone's efficacy confirmed; time to aim higher. Lancet Oncology, The, 2015, 16, 119-121.	5.1	1
151	Radium-223 in prostate cancer: emitting the right signals. Lancet Oncology, The, 2016, 17, 1186-1187.	5.1	1
152	Docetaxel extravasation: Pathologic correlation and treatment with intralesional steroids. JAAD Case Reports, 2017, 3, 322-325.	0.4	1
153	Expanding the use of abiraterone in prostate cancer: Is earlier always better?. Cancer Biology and Therapy, 2018, 19, 97-100.	1.5	1
154	Life under the CABOSUN: Cabozantinib improves quality-adjusted survival in comparison with sunitinib. Cancer, 2020, 126, 5210-5212.	2.0	1
155	A pilot study on the clinical value of 18F-sodium fluoride PET/CT in advanced prostate cancer.. Journal of Clinical Oncology, 2012, 30, 10589-10589.	0.8	1
156	Personalized peptide vaccine in prostate cancer: capitalizing on existing immunity. Translational Cancer Research, 2016, 5, S1333-S1335.	0.4	1
157	Evolving role of chemotherapy in castration-resistant prostate cancer. Clinical Practice (London,) Tj ETQq1 1 0.784314 rgBT /Overlock 0.1	0.1	0
158	Novel immunotherapeutic agents for castration-resistant prostate cancer: update from clinical trials. Clinical Investigation, 2013, 3, 651-663.	0.0	0
159	Therapeutic Cancer Vaccines: An Emerging Approach to Cancer Treatment. Cancer Drug Discovery and Development, 2014, , 553-568.	0.2	0
160	Real-world experience with abiraterone. Lancet Oncology, The, 2014, 15, 1188-1190.	5.1	0
161	Anaplastic Features in Advanced Prostate Cancer With and Without DNA Damage Repair Mutations. Clinical Genitourinary Cancer, 2021, 19, e352-e359.	0.9	0
162	Cancer Immunology, Immunotherapeutics, and Vaccine Approaches. , 2010, , 305-319.		0

#	ARTICLE	IF	CITATIONS
163	A method for assessing tumor response to therapy and more precisely guiding treatment decisions so as to improve survival.. Journal of Clinical Oncology, 2012, 30, e13122-e13122.	0.8	0
164	Assessment of Aortoiliac Atherosclerotic Plaque on CT in Prostate Cancer Patients Undergoing Treatment. Tomography, 2022, 8, 607-616.	0.8	0